Phaseline

Companies › Incepta Pharmaceuticals

Incepta Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 8 registered trials: 5 Phase 3, 2 Phase 4, 1 Phase 1; Neurology, Hematology, Other.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Epoetin Alfa
Erythropoietin receptor agonist
EPORPhase 3Healthy; Hypobaric Hypoxia; Anemia; Encephalopathy …–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05300477Epoetin AlfaPhase 4Hypobaric HypoxiaOtherSep 2023
NCT07025681Epoetin AlfaPhase 3HealthyOtherSep 2025
NCT05395195Epoetin AlfaPhase 3EncephalopathyNeurologyDec 2026
NCT06670963Epoetin AlfaPhase 4AnemiaHematologyDec 2026
NCT04588311Epoetin AlfaPhase 3TraumaNeurologyDec 2026
NCT00843882Epoetin AlfaPhase 3AnemiaHematologyMay 2027
NCT03223961Epoetin AlfaPhase 3Myelodysplastic SyndromesHematologyOct 2028
NCT06832189Epoetin AlfaPhase 1Liver TransplantOtherJun 2030

Targets

EPOR (1)

Companies with the same targets

Takeda Genexine Biocad

Companies built like this

Chongqing Claruvis Pharmaceutical Kedrion CellTherX Pharmazz Sandoz

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.